|
|
|
|
|
| October 6, 2011 | ISSUE NUMBER 220 VOL 8 |
Advertising
DTC a 'Fundamental Right', says Pfizer CEO
Denying the right of industry to speak directly to patients through drug advertising “leads to ignorance and the inability to judge,” said Ian Read, Pfizer’s President and CEO. Asked whether DTC ads on television should be retired, Read answered unequivocally: “No” ...Read More
R&D
Prix Galien Winners Embody Innovation
The winners of the fifth annual Prix Galien USA, held in New York last week, represent the progress of the entire industry and shows us how far it has come in advancing the pace of innovation and commercializing new medicines
...Read More
Global
30 Years of European Pharma: Survival of the Fittest?
This month sees Pharmaceutical Executive reach its 30th birthday. In line with that milestone, Reflector assesses what the last three decades have meant for European pharma—and shows how the game has changed beyond recognition ...Read More
Vaccines
What Patients Don't Know Could Hurt Drug Makers
A recent poll revealed that 21 percent of respondents believed that autism was linked to vaccines, and 7 percent believed that diabetes was linked to vaccines. Nearly half of the respondents worried about the side effects of vaccines, and about the same portion were concerned about their long-term effects on health. Is it the time to launch another public-education program? ...Read more |
|
|
 // The acquisition of Nycomed (Switzerland) by Japan's Takeda for € 9.6 billion euros saw Dr Frank Morich named as CEO of Nycomed in addition to his current role as Executive Vice President, International Operations (Americas/Europe), Takeda Pharmaceuticals International (Deerfield, Ill.) // Galena Biopharma (Lake Oswego, Ore.) announced the appointment of Hana B. Moran, Ph.D., as Vice President, Regulatory Affairs and Compliance, effective immediately. // NovaBay Pharmaceuticals (Emeryville, Calif.) named David W. Stroman, Ph.D., as Senior Vice President, Ophthalmic Drug Development. //
The Bayer Healthcare plant in Berkeley, Calif, agreed to a proposal that includes better job security measures, controls on health care insurance costs, and annual raises of more than 3 percent during the four-year contract for its 420 pharmaceutical workers. The proposed agreement is subject to a membership ratification vote scheduled for Oct.12. |
|
|
|
|
|
|
|
|
|
|
 |
| |
|
| |
 |
| |
 |
|
 |
Who should be driving universal anti-counterfeiting solutions?
a) Pharma
b) Regulators
c) Vendors?
|
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To
ensure delivery to your Inbox, please add us to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
